Form4insider filings, from the source

SEC Form 4 · accession 0001415889-18-001321

Vistagen Therapeutics, Inc. · VTGN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
H. Ralph Snodgrass
Officer — PRES./CHIEF SCIENTIFIC OFFICER · Director
Period of report
Aug 29, 2018
Accepted (ET)
Aug 31, 2018 · 5:27 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411685

Table I — non-derivative securities

No Table I lines on this filing.

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (Right to Buy)F1$10.00Aug 29, 2018D2,500DMar 24, 2013Mar 24, 2019Common Stock2,5000D
Stock Option (Right to Buy)$1.50Aug 29, 2018A2,500AAug 29, 2018Mar 24, 2019Common Stock2,5002,500D
Stock Option (Right to Buy)F2$10.00Aug 29, 2018D1,250DDec 17, 2009Jun 17, 2019Common Stock1,2500D
Stock Option (Right to Buy)$1.50Aug 29, 2018A1,250AAug 29, 2018Jun 17, 2019Common Stock1,2501,250D
Stock Option (Right to Buy)F3$10.00Aug 29, 2018D12,500DDec 31, 2012Dec 30, 2019Common Stock12,5000D
Stock Option (Right to Buy)$1.50Aug 29, 2018A12,500AAug 29, 2018Dec 30, 2019Common Stock12,50012,500D
Stock Option (Right to Buy)F4,F5$3.49Aug 29, 2018D125,000D—Jun 19, 2026Common Stock125,0000D
Stock Option (Right to Buy)F5$1.50Aug 29, 2018A125,000A—Jun 19, 2026Common Stock125,000125,000D
Stock Option (Right to Buy)F6,F7$3.80Aug 29, 2018D80,000D—Nov 9, 2026Common Stock80,0000D
Stock Option (Right to Buy)F7$1.50Aug 29, 2018A80,000A—Nov 9, 2026Common Stock80,00080,000D
Stock Option (Right to Buy)F8,F9$1.96Aug 29, 2018D125,000D—Apr 26, 2027Common Stock125,0000D
Stock Option (Right to Buy)F9$1.50Aug 29, 2018A125,000A—Apr 26, 2027Common Stock125,000125,000D

Explanation of responses